skip to main content
Language:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters

Results 1 - 20 of 5,617  for All Library Resources

Results 1 2 3 4 5 next page
Refined by: Journal Title: Business Wire remove subject: Health Aspects remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Komodo Health Partners Present 33 Real-World Evidence Research Studies at ISPOR 2024
Material Type:
Newspaper Article
Add to My Research

Komodo Health Partners Present 33 Real-World Evidence Research Studies at ISPOR 2024

Business Wire, 2024-05-06

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

2
John Hopkin's University Publishes Efficacy of QuadraMune Ingredient Sulforaphane at Inhibiting Coronavirus in Laboratory Studies
Material Type:
Newspaper Article
Add to My Research

John Hopkin's University Publishes Efficacy of QuadraMune Ingredient Sulforaphane at Inhibiting Coronavirus in Laboratory Studies

Business Wire, 2022-05-27

COPYRIGHT 2022 Business Wire, Inc.

Digital Resources/Online E-Resources

3
Fractyl Health Demonstrated Significant Improvement in Weight Loss in Head-to-Head Preclinical Obesity Studies of its Rejuva GLP-1-Based Pancreatic Gene Therapy Candidate (GLP-1 PGTx) Compared to Chronic Semaglutide at EASD's Annual Meeting
Material Type:
Newspaper Article
Add to My Research

Fractyl Health Demonstrated Significant Improvement in Weight Loss in Head-to-Head Preclinical Obesity Studies of its Rejuva GLP-1-Based Pancreatic Gene Therapy Candidate (GLP-1 PGTx) Compared to Chronic Semaglutide at EASD's Annual Meeting

Business Wire, 2023-10-04

COPYRIGHT 2023 Business Wire, Inc.

Digital Resources/Online E-Resources

4
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies
Material Type:
Newspaper Article
Add to My Research

EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies

Business Wire, 2022-03-21

COPYRIGHT 2022 Business Wire, Inc.

Digital Resources/Online E-Resources

5
Laboratory Studies Confirm BETADINE Antiseptic Products' Effectiveness Against COVID-19 Virus
Material Type:
Newspaper Article
Add to My Research

Laboratory Studies Confirm BETADINE Antiseptic Products' Effectiveness Against COVID-19 Virus

Business Wire, 2020-07-09

COPYRIGHT 2020 Business Wire, Inc.

Digital Resources/Online E-Resources

6
Laboratory Studies Confirm the Effectiveness of BETADINE Gargle and Mouthwash Against COVID-19 Virus
Material Type:
Newspaper Article
Add to My Research

Laboratory Studies Confirm the Effectiveness of BETADINE Gargle and Mouthwash Against COVID-19 Virus

Business Wire, 2020-06-30

COPYRIGHT 2020 Business Wire, Inc.

Digital Resources/Online E-Resources

7
Fractyl Health Demonstrates Significant Improvement in Glucose Control and Obesity in Preclinical Studies of its Rejuva GLP-1 Based Pancreatic Gene Therapy (GLP1 PGTx) Compared to Chronic Semaglutide at ADA's 83rd Scientific Sessions
Material Type:
Newspaper Article
Add to My Research

Fractyl Health Demonstrates Significant Improvement in Glucose Control and Obesity in Preclinical Studies of its Rejuva GLP-1 Based Pancreatic Gene Therapy (GLP1 PGTx) Compared to Chronic Semaglutide at ADA's 83rd Scientific Sessions

Business Wire, 2023-06-24

COPYRIGHT 2023 Business Wire, Inc.

Digital Resources/Online E-Resources

8
New Studies Conclude Xlear Kills and/or Deactivates SARS-CoV-2
Material Type:
Newspaper Article
Add to My Research

New Studies Conclude Xlear Kills and/or Deactivates SARS-CoV-2

Business Wire, 2020-11-30

COPYRIGHT 2020 Business Wire, Inc.

Digital Resources/Online E-Resources

9
Immunicom Presents Promising Preliminary Data from Immunopheresis Studies in Late-Stage Cancer Patients at JCA-AACR 2021
Material Type:
Newspaper Article
Add to My Research

Immunicom Presents Promising Preliminary Data from Immunopheresis Studies in Late-Stage Cancer Patients at JCA-AACR 2021

Business Wire, 2021-09-14

COPYRIGHT 2021 Business Wire, Inc.

Digital Resources/Online E-Resources

10
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting in the US
Material Type:
Newspaper Article
Add to My Research

New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting in the US

Business Wire, 2024-05-09

COPYRIGHT 2024 Business Wire, Inc.

Digital Resources/Online E-Resources

11
Swing Therapeutics Announces Positive Results from Studies of Stanza, a Digital Therapeutic for Fibromyalgia Treatment
Material Type:
Newspaper Article
Add to My Research

Swing Therapeutics Announces Positive Results from Studies of Stanza, a Digital Therapeutic for Fibromyalgia Treatment

Business Wire, 2022-11-21

COPYRIGHT 2022 Business Wire, Inc.

Digital Resources/Online E-Resources

12
Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting
Material Type:
Newspaper Article
Add to My Research

Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting

Business Wire, 2022-05-24

COPYRIGHT 2022 Business Wire, Inc.

Digital Resources/Online E-Resources

13
Enanta Pharmaceuticals Completes Enrollment in Two Ongoing Phase 2 Studies
Material Type:
Newspaper Article
Add to My Research

Enanta Pharmaceuticals Completes Enrollment in Two Ongoing Phase 2 Studies

Business Wire, 2019-03-18

COPYRIGHT 2019 Business Wire, Inc.

Digital Resources/Online E-Resources

14
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
Material Type:
Newspaper Article
Add to My Research

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

Business Wire, 2022-05-23

COPYRIGHT 2022 Business Wire, Inc.

Digital Resources/Online E-Resources

15
Published Research Shows Initial Results from SARS-CoV-2 Surveillance Studies Support U.S. Public Health Initiatives
Material Type:
Newspaper Article
Add to My Research

Published Research Shows Initial Results from SARS-CoV-2 Surveillance Studies Support U.S. Public Health Initiatives

Business Wire, 2022-04-27

COPYRIGHT 2022 Business Wire, Inc.

Digital Resources/Online E-Resources

16
Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology Infectious Diseases (ECCMID)
Material Type:
Newspaper Article
Add to My Research

Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology Infectious Diseases (ECCMID)

Business Wire, 2021-07-12

COPYRIGHT 2021 Business Wire, Inc.

Digital Resources/Online E-Resources

17
Preclinical Studies From Vaxxas and Collaborators Reveal Potential of Vaxxas' Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike Vaccine
Material Type:
Newspaper Article
Add to My Research

Preclinical Studies From Vaxxas and Collaborators Reveal Potential of Vaxxas' Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike Vaccine

Business Wire, 2021-06-02

COPYRIGHT 2021 Business Wire, Inc.

Digital Resources/Online E-Resources

18
New Studies Highlight Activity of XERAVA Against Gram-Negative and Gram-Positive Clinical Isolates, Including Multidrug-Resistant Pathogens
Material Type:
Newspaper Article
Add to My Research

New Studies Highlight Activity of XERAVA Against Gram-Negative and Gram-Positive Clinical Isolates, Including Multidrug-Resistant Pathogens

Business Wire, 2019-06-24

COPYRIGHT 2019 Business Wire, Inc.

Digital Resources/Online E-Resources

19
bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111)
Material Type:
Newspaper Article
Add to My Research

bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111)

Business Wire, 2021-02-16

COPYRIGHT 2021 Business Wire, Inc.

Digital Resources/Online E-Resources

20
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and -Thalassemia Studies
Material Type:
Newspaper Article
Add to My Research

bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and -Thalassemia Studies

Business Wire, 2021-06-07

COPYRIGHT 2021 Business Wire, Inc.

Digital Resources/Online E-Resources

Results 1 - 20 of 5,617  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
  1. Before 2007  (107)
  2. 2007 To 2010  (499)
  3. 2011 To 2014  (1,044)
  4. 2015 To 2019  (1,355)
  5. After 2019  (2,613)
  6. More options open sub menu

Searching Remote Databases, Please Wait